# Treatment of ADHD With Atomoxetine in Children & Adolescents With ADHD & Comorbid Dyslexia

> **NCT00607919** · PHASE4 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 209 (actual)

## Conditions studied

- Attention Deficit Hyperactivity Disorder
- Dyslexia

## Interventions

- **DRUG:** Atomoxetine
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00607919
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-03
- **Primary completion:** 2010-11
- **Final completion:** 2011-02
- **Target enrollment:** 209 (ACTUAL)
- **Last updated:** 2011-12-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00607919

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00607919, "Treatment of ADHD With Atomoxetine in Children & Adolescents With ADHD & Comorbid Dyslexia". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00607919. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*